<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679119</url>
  </required_header>
  <id_info>
    <org_study_id>UCL 11/0475</org_study_id>
    <nct_id>NCT01679119</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy</brief_title>
  <acronym>INCA</acronym>
  <official_title>A Randomised Phase II Trial of Inotuzumab Ozogamicin Plus Rituximab &amp; CVP (IO-R-CVP) vs Gemcitabine Plus Rituximab &amp; CVP (Gem-R-CVP) for the First Line Treatment of Patients With DLBCL Who Are Not Suitable for Anthracycline Containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in
      combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell
      Lymphoma (DLBCL) in a population of patients not suitable for anthracycline based
      chemotherapy.

      There is no standard of care for the treatment of this group of patients. If demonstrated to
      be efficacious and safe to deliver this regimen will be further tested in a phase III trial
      to determine whether this should become the standard of care amongst patients with DLBCL not
      fit for anthracycline (R-CHOP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of DLBCL is increasing and with an expanding elderly population, the incidence
      will continue to rise. Given that about 40% of cases of DLBCL occur in patients aged over 70
      and the number of co-mobilities increases with age, research to investigate the optimal
      treatment of DLBCL in this group of patients is needed. R-CHOP remains the standard of care
      for the majority of patients with DLBCL, anthracycline use is precluded in a proportion of
      these patients by a high risk of developing cardiotoxicity, especially congestive cardiac
      failure. Currently there is no standard of care for patients who are unfit for anthracycline
      treatment. It has been routine to omit the doxorubicin from R-CHOP, giving R-CVP instead.
      However the outcome for patients treated with R-CVP is poor and attempts have been made to
      replace the doxorubicin with alternative agents. The trial will compare an experimental arm
      consisting of Inotuzumab Ozogamicin added to the standard immunochemotherapy regimen of
      rituximab, cyclophosphamide, vincristine and prednisolone (R-CVP) with the control arm of
      gemcitabine added to the same combination (Gem-R-CVP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 2 years following date of randomisation.</time_frame>
    <description>Progression free survival rate and will be analysed using Kaplan-Meier survival analysis. PFS time will be measured from date of randomisation until progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Approximately 6 months after treatment start</time_frame>
    <description>At the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years from date of registration</time_frame>
    <description>Date of registration until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicity</measure>
    <time_frame>7 months from beginning of treatment</time_frame>
    <description>During treatment and follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, during treatment and 6 month and 2 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance status post treatment</measure>
    <time_frame>Baseline, every 21 days for 8 cycles, 5 1/2 months at the end of treatment and then up to 3 years after the end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-morbidities of patients</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>IO-R-CVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine &amp; prednisolone).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-R-CVP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750mg/m2 IV, given day 1</description>
    <arm_group_label>IO-R-CVP</arm_group_label>
    <arm_group_label>Gem-R-CVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4mg/m2(max 2mg)IV given day 1</description>
    <arm_group_label>IO-R-CVP</arm_group_label>
    <arm_group_label>Gem-R-CVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 100mg OD Oral given days 1-5</description>
    <arm_group_label>IO-R-CVP</arm_group_label>
    <arm_group_label>Gem-R-CVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375mg/m2 IV given day 1</description>
    <arm_group_label>IO-R-CVP</arm_group_label>
    <arm_group_label>Gem-R-CVP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin</intervention_name>
    <description>Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2</description>
    <arm_group_label>IO-R-CVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)</description>
    <arm_group_label>Gem-R-CVP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Informed written consent for the trial

          -  Histologically proven diffuse large B cell lymphoma (DLBCL) according to the current
             World Health Organisation (WHO) classification including all morphological variants.
             The B cell nature of the proliferation must be verified by demonstration of CD20
             positivity. A concurrent (synchronous) diagnosis of low grade lymphoma (e.g. on bone
             marrow trephine or presence of both low grade and DLBCL in a lymph node biopsy) or
             previous diagnosis of low grade lymphoma which hasn't been treated with a systemic
             therapy is permitted

          -  Bulky Stage IA (lymph node or lymph node mass ≥ 10cm in maximum diameter), stage IB,
             stage II, stage III and stage IV disease

          -  ECOG performance status 0-2

          -  Measurable disease

          -  Age 18 ≥ years

          -  Adequate contraceptive precautions for all patients of childbearing potential

          -  History of malignant disease diagnosed at any time in the past with completed radical
             treatment and the risk of relapsing within the next 5 years is &lt;10%. Patients
             previously treated should be free of sequelae of treatment which would compromise the
             delivery of study drugs as compared with other eligible patients.

          -  No previous chemotherapy, radiotherapy or other investigational drug for this
             indication - previous corticosteroids up to a dose equivalent to prednisolone
             1mg/kg/day for up to 14 days are permitted prior to randomisation EITHER

          -  Unsuitable for anthracycline-containing chemotherapy due to impaired cardiac function
             defined by an ejection fraction of ≤ 50% OR Left ventricle ejection fraction &gt; 50% but
             in the presence of significant co-morbidities (diabetes mellitus, hypertension or
             ischaemic heart disease) precluding anthracycline-containing chemotherapy as
             determined by treating physician. Co-morbidities must be documented on the
             randomisation form and CIRS score recorded

          -  Adequate bone marrow function (Platelets &gt; 100x109/l, WBC &gt; 3.0x109/l, Neutrophils &gt;
             1.5x109/l) at time of study entry unless attributed to bone marrow infiltration by
             DLBCL

          -  Life expectancy &gt; 3 months

        Exclusion criteria:

          -  Symptomatic central nervous system or meningeal involvement by DLBCL

          -  Previous diagnosis of low grade lymphoma which has been treated with a systemic
             therapy

          -  Non-bulky stage IA disease

          -  ECOG performance status 3-4

          -  History of chronic liver disease or suspected alcohol abuse

          -  Serum bilirubin greater than upper limit of normal unless attributable to Gilberts
             syndrome or haemolysis

          -  Alanine and/or aspartate aminotransferase levels (ALT and/or AST) and alkaline
             phosphatase (ALP) greater than 2.5 times the upper limit of normal

          -  Glomerular filtration rate (GFR) &lt; 30ml/min. GFR calculated by Cockroft-Gault (not
             eGFR).

          -  Serological evidence of active hepatitis B or C infection whether acute or chronic
             (defined as positive anti-HCV serology; positive HBsAg). All positive HBcAb results
             should also be excluded on safety grounds regardless of HBsAg or HBV DNA status.
             Antibodies to Hepatitis B surface antigen (anti-HBs) due to a history of past
             vaccination is acceptable

          -  Known history of HIV seropositive status

          -  Patients with a history of Venoocclusive Disease (VOD) and Sinusoidal Obstructive
             Syndrome (SOS)

          -  Patients with a screening of QTcF interval &gt;470msec

          -  Medical or psychiatric conditions compromising the patient's ability to give informed
             consent

          -  Women who are pregnant or lactating

          -  LVEF &gt; 50% in the absence of significant co-morbidities that preclude anthracycline
             use

          -  Patients with a history of severe allergic/anaphylactic reaction to any humanised
             monoclonal antibody

          -  Patients with serious active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew McMillan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>INCA Trial Coordinator</last_name>
    <phone>+ 44 2076799860</phone>
    <email>ctc.inca@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stoke Mandeville Hospital (including Wycombe Hospital)</name>
      <address>
        <city>Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beena Pushkaran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noel Ryman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Knechtli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Walewska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Lowry</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamtha Karanth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rusell Patmore</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Coventry</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Watt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tariq Shafi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Kerry</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maadh Abdul-Wahab Aldouri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre (including Gartnavel Royal Hospital)</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam McKay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital</name>
      <address>
        <city>Great Yarmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalal Sadullah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicki Panoskaltsis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kettering General Hospital</name>
      <address>
        <city>Kettering</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Lyttelton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Burton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Miall</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery Smith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagesh Kalakonda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital (including St Thomas's Hospital)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Fields</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Cwynarski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luton and Dunstable Hospital</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hoskin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Linton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lennard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Tyneside Hosptial (including Wansbeck Hospital and Hexham General Hospital)</name>
      <address>
        <city>North Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Kilner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimish Shah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McMillan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Royal University Hospital</name>
      <address>
        <city>Orpington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Collins</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Rule</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Greaves</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andy Davies</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Turner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryson Pottinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hampshire County Hospital</name>
      <address>
        <city>Winchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Lowndes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcester Royal Hospital (including Kidderminster Hospital and Alexandra Hospital)</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Crowther</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital (including Trafford General Hospital)</name>
      <address>
        <city>Wythenshawe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Watt</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large b cell lymphoma</keyword>
  <keyword>Inotuzumab Ozogamicin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

